OpenNeedle Ask your own

Question explored with the scientific record

Long Covid, what is the time to get over it

Sep 3, 2026 · 7 sources used · OpenNeedle synthesis
The honest answer: there is no single "time to get over" long COVID. Recovery varies wildly, and the evidence shows that for many, symptoms persist well past a year.

The best data comes from a 2021 multicenter cohort of 796 survivors of severe COVID-19. At six months, over half (55.4%) still had at least one symptom, most commonly fatigue, sleep disturbance, and shortness of breath [9]. A 2025 bioinformatic study found that gene expression in the blood of recovered patients remained abnormal up to 24 weeks after infection, with mitochondrial and inflammatory pathways still perturbed [4]. That is not a quick recovery.

A 2022 case report of a previously healthy 27-year-old runner who developed severe POTS (postural orthostatic tachycardia syndrome) after a mild infection shows the other end of the spectrum. She improved gradually over a year with lifestyle changes and exercise, but was still unable to return to work at the 12-month mark [6]. A 2021 review of olfactory dysfunction found that about 24.5% of patients took more than two months to recover their sense of smell, and a quarter of those still had not recovered at that point [3].

The evidence does not support a neat timeline. A 2021 nationally representative survey of 608 adults found that about half still reported symptoms three months after diagnosis, and age was not a significant predictor of who became a "long-hauler" [20]. A 2024 overview of 194 studies (735,006 participants) with a mean follow-up of 126 days found fatigue prevalence at 28.4% in hospitalized and 34.8% in non-hospitalized patients [28]. The Korean clinical practice guideline defines PASC as symptoms persisting beyond three months [22].

PopulationKey findingTime pointSource
796 severe COVID survivors55.4% had at least one symptom6 months[9]
608 adults (national survey)~50% still symptomatic3 months[20]
27-year-old runner (POTS case)Still unable to work12 months[6]
Olfactory dysfunction cohort24.5% not recovered>2 months[3]
Meta-analysis (194 studies, 735k patients)Fatigue in 28-35%Mean 126 days[28]

My call: long COVID is not a condition with a predictable recovery window. A substantial fraction of patients, especially those with fatigue, dysautonomia, or cognitive symptoms, remain impaired at six months and beyond. The evidence does not support telling anyone they will "get over it" in weeks or months. Confidence: high.

Keep digging

Sources used 7

  1. Clinical features, pathogenesis and treatment of long-haul COVID‑19 impact on nervous system Medical alphabet (2021) Thin

    A clinical review detailing long-term neurological sequelae of COVID-19, with emphasis on olfactory and gustatory dysfunction and autonomic neuropathy, and proposing multidisciplinary rehabilitation and neuroregenerative pharmacotherapies.

    DOI: 10.33667/2078-5631-2021-3-14-22
  2. Peripheral blood, lung and brain gene signatures in recovered and deceased patients with COVID-19 In Silico Pharmacology (2025) Thin

    A bioinformatic reanalysis of bulk RNA-seq data from blood, lung, and brain of recovered and deceased COVID-19 patients reveals persistent nuclear-encoded mitochondrial gene perturbations, IL-6–centric inflammatory signatures across tissues, and links between initial disease sev…

    DOI: 10.1007/s40203-025-00450-1
  3. Severe Post-COVID-19 dysautonomia: a case report BMC Infectious Diseases (2022) Mixed

    A previously healthy 27-year-old female runner developed severe postural orthostatic tachycardia syndrome (POTS) and debilitating dysautonomia approximately five weeks after a mild COVID-19 infection, with symptoms including post-exertional fatigue, cognitive slowing, palpitatio…

    DOI: 10.1186/s12879-022-07181-0
  4. Half‐year follow‐up of patients recovering from severe COVID‐19: Analysis of symptoms and their risk factors Journal of Internal Medicine (2021) Thin

    A multicenter cohort study following 796 survivors of severe COVID-19 for six months to characterize long-term sequelae, antibody persistence, and associated risk factors, finding that over half had at least one symptom (notably fatigue, sleep disturbance, and dyspnea) with fema…

    DOI: 10.1111/joim.13284
  5. Age Differences in Becoming COVID Long-Haulers and in Post-Acute Sequelae of SARS-CoV-2 Innovation in Aging (2021) primary study Strong

    In a nationally representative sample of 608 adults with COVID-19, age was not a significant determinant of post-acute sequelae symptom count or becoming a long-hauler, with about half reporting symptoms three months after diagnosis.

    DOI: 10.1093/geroni/igab046.054
  6. Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 Infection & Chemotherapy (2025) Thin

    A Korean Clinical Practice Guideline revision updating evidence-based recommendations for the diagnosis, evaluation, treatment, and prevention of Post-Acute Sequelae of COVID-19 (PASC), emphasizing multidisciplinary care, early antiviral therapy, vaccination to reduce risk, and …

    DOI: 10.3947/ic.2025.0151
  7. Long COVID: A Comprehensive Overview of the Signs and Symptoms across Multiple Organ Systems Korean Journal of Family Medicine (2024) Thin

    This study provides a comprehensive overview of the signs and symptoms of Long COVID across multiple organ systems, highlighting the complexity and variability of post-acute sequelae of COVID-19.

    DOI: 10.4082/kjfm.24.0085

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question